Eµ-BRD2 transgenic mice develop B-cell lymphoma and leukemia

Rebecca J. Greenwald, Joseph R. Tumang, Anupama Sinha, Nicolas Currier, Robert D. Cardiff, Thomas L. Rothstein, Douglas V. Faller, and Gerald V. Denis

Transgenic mice with lymphoid-restricted overexpression of the double bromodomain protein bromodomain-containing 2 (Brd2) develop splenic B-cell lymphoma and, upon transplantation, B-cell leukemia with leukemic infiltrates in liver and lung. Brd2 is a nuclear-localized transcription factor kinase that is most closely related to TATA box binding protein–associated factor, 250 kDa (TAFII250) and the Drosophila developmental protein female sterile homeotic. Constitutive expression of BRD2 in the lymphoid compartment increases cyclin A transcription, “priming” transgenic B cells for proliferation. Mice stochastically develop an aggressive B-cell lymphoma with the features of B1 cells, including CD5 and surface IgM expression. The B-cell lymphoma is monoclonal for immunoglobulin gene rearrangement and is phenotypically stable. The lymphoblasts are very large and express a transcriptome that is similar to human non-Hodgkin lymphomas. Both a wild-type BRD2 transgene and a kinase-null point mutant drive lymphomagenesis; therefore we propose that, rather than kinase activity, Brd2-mediated recruitment of E2 promoter binding factors (E2Fs) and a specific histone acetyltransferase to the cyclin A promoter by both types of transgene is a mechanistic basis for neoplasia. This report is the first to describe a transgenic mouse model for constitutive expression of a protein with more than one bromodomain.

© 2004 by The American Society of Hematology
(MEKK), a ras effector, but wild-type does; however, both forms transactivate synergistically with oncogenic ras (G.V.D., unpublished data, December 2002). These results likely mean that both kinase-dependent and independent ras pathways are involved in Brd2 transformation. Ectopically expressed Brd2 transactivates endogenous cyclin A and accelerates the G1 → S transition (A.S., G.V.D., unpublished data, May 2003), providing a mechanism for its observed transforming properties.

A logical next step was developing a transgenic mouse model, wherein constitutive overexpression of recombinant Brd2 would be predicted to deregulate the cell cycle and lead to transformation. We used a murine immunoglobulin (Ig) heavy-chain promoter-enhancer construct plgTE/N to express BRD2 cDNA in the lymphoid compartment (Eμ-BRD2; transgenic [Tg]), or the same vector incorporating a kinase-inactive point mutant (Eμ-BRD2mut), to test the hypothesis that kinase activity is linked to oncogenesis. The Eμ system has been used successfully to express myc in the B lineage to produce B-cell11 and pre-B-cell32 lymphomas and the α subunit of casein kinase II in the T lineage to produce thymomas.33 Malignancies arise stochastically in these models and in Eμ-BRD2 mice: transgene expression is elevated in B cells but not T cells or other tissues; they sporadically develop a B-cell lymphoma. The malignancy is monoclonal, transplantable, and phenotypically uniform, bearing many of the hallmarks of B-1 cells.34 Both Tg and Tgmut mice develop the same disease but littermate controls do not. This result suggests that intrinsic kinase activity of Brd2 is not required for oncogenesis in this system and evinces that BRD2 has oncogenic properties in vivo.

### Materials and methods

#### Molecular cloning

A consensus Kozak sequence was engineered into the 2.28-kilobase (kb) human Brd2 cDNA with Vent DNA Polymerase (New England Biolabs, Beverly, MA). The cDNA was cloned into the Xhol site of plgTE/N and propagated in Escherichia coli STBL2 (Invitrogen Life Technologies, Carlsbad, CA). Restriction analysis and DNA sequencing verified the Tg construct. A Tg construct harboring a kinase-inactive point mutant (Tgmut) was generated simultaneously (TgmutK574A) from this plasmid. A 5.22-kb SalI/MluI fragment containing the Eμ enhancer and simian virus 40 (SV40) poly A was purified and injected into FVB oocytes.

#### Construction of transgenic mice and genotyping

Southern blotting and polymerase chain reaction (PCR) analysis of tail DNA identified founders. A primer set distinguished between endogenous and transgenic DNA (5′-CAAGAGGCTGACTACCTGCCTC3′ and 5′-AGGAGGGCTCTGAGAGAACAGAGGAGC-3′). Taq DNA Polymerase (Invitrogen Life Technologies) amplified the templates in 2.0 mM Mg++ for 35 cycles at a melting temperature of 94°C (ta=30 seconds), an annealing temperature of 68°C (ta=1 minute), and an extension temperature of 72°C (ta=1 minute). Three Tg founders and 10 Tgmut founders were obtained; breeding lines were culled to 2 Tg and 2 Tgmut lines, based on transgene passage and mRNA expression.

#### Expression analysis

Anti-CD45R (B220) or anti-CD3 magnetic beads (Miltenyi Biotec, Auburn, CA) positively selected B or T cells, respectively, from spleens, in phosphate-buffered saline (PBS) supplemented with 2 mM ethylenediaminetetraacetic acid (EDTA) and 0.5% bovine serum albumin. RNA was isolated from purified B and T cells or other tissues by guanidinium denaturation, resolved, blotted, and detected with a BRD2 probe in ExpressHyb (BD Biosciences, Palo Alto, CA). To detect cyclin A, transgene, or Ig gene expression, RNA was reverse-transcribed with random hexamer primers using ImProm-II reverse transcriptase (RT; Promega, Madison, WI) and amplified with PCR. The cyclin A gene was amplified with Taq DNA Polymerase (Invitrogen Life Technologies) using primers 5′-TGAAGGCGGGAAGTGTGGACCCCGGC-3′; 5′-CTTCTC- CACCTCAACAGCCAGTCCAAAC-3′; and 5′-CTTCTGGAGTA- AAGTGTACACCAATGCAC-3′. 3′-TGGTCGCTGGGTCGCCG- CTAGCAAGGAGG-3′ in 2.5 mM Mg++ for 40 cycles at 95°C (ta=1 min), 55°C (ta=1 min), and 72°C (ta=1.5 min). The BRD2 transgene was amplified with forward primer 5′-CTCGAGGGCCGCCATGGTCC- GTG-3′ and reverse primer 5′-AGTACCGCTTACATGCTG-3′ in 2.0 mM Mg++ for 35 cycles at 94°C (ta=30 s), 68°C (ta=30 s), and 72°C (ta=1 min). Ig gene cDNA templates were amplified with 3′ primers to constant regions of expressed Ig genes and degenerate 5′ primers to variable regions.35 Engineered EcoRI sites permitted cloning and sequencing. Primers were 3′C, 5′-CCCGAATTCTGCTCGGAGGAC-3′; 3′C, 5′-CCCGAATTCTA- GTGCTCAGTCCA-3′; 5′Vi, 5′-CCCGAATTCTGAGTGAACTGGTG- GGAGA/CTGGG-3′; 5′Vi2, 5′-CCCGAATTCTGAGTGAACTGGTG- CGA/CTGGG-3′; 5′V1, 5′-CCCGAATTCTGAGTGAACTGGTG- CGA/CTGGG-3′; 5′V2, 5′-CCCGAATTCTGAGTGAACTGGTG- CGA/CTGGG-3′; 5′V3, 5′-CCCGAATTCTGAGTGAACTGGTG- CGA/CTGGG-3′; and were used in pairs to amplify expressed Ig gene κ chains in 2.5 mM Mg++ for 30 cycles at 95°C (ta=1 min), 55°C (ta=1 min), and 72°C (ta=2 min). PCR products were resolved in ethidium bromide and DNA fluorescence was measured. If the gene product was derived from a polyclonal Ig gene, a smear was expected after gel separation, but if the Ig gene was monoclonal, a single band was expected. Single bands were isolated and cloned into a plasmid for cDNA expression pCNA(D) (Amp) (Invitrogen Life Technologies) for sequencing.

To assess B-cell chronic lymphocytic leukemia lymphoma 6 (Bcl6), B-lymphocyte–induced maturation protein-1 (Blimp-1), or β2-microglobulin expression, cDNA was amplified with a real-time PCR detection system (BioRad, Richmond, CA) using primers 5′-GACAATT CTACTGCCCAAGG-3′; 5′-CTTCTCTTCTTGTGCTCTTGGTGC-3′; and 5′-AAGAGGT- TATGGGGCTGGAAG-3′; 5′-ACTCTCTGGGTGGACATTTGGG-3′; and 5′-CCCGCCCCTACCATTGAATCC-3′; 5′-GGTATGTCATGCTCTC- GTGG-3′ correspondingly for 40 cycles at 95°C (ta=0.5 min) and 62°C (ta=1 min).

#### Flow cytometry

Single cell suspensions were prepared from spleen, thymus, or lymph nodes in Hanks buffered salt solution (HBSS) after erythrocyte lysis and stained in PBS supplemented with 0.1% bovine serum albumin. Peritoneal washes were prepared with 5 mL of HBSS. Fluorescein isothiocyanate (FITC)– and phycoerythrin (PE)–coupled antibodies against mouse CD5, CD11b, CD19, CD49b, CD117, CD127, IgM, and Ly-6G for surface cytometric analyses were from eBioscience (San Diego, CA). Antibodies against CD4, CD5, CD8, CD9, CD11b, CD25, CD44, CD62L, CD9, B220, B7-1, B7-2, Syndecan-1, and rat isotype controls were from BD Pharmingen (San Diego, CA). Proliferation was measured in triplicate by quadruplication of [3H] thymidine (New England Nuclear, Boston, MA).

#### Histology

Tissue sections were fixed overnight in 10% formalin in PBS, preserved in 70% ethanol, mounted, and stained with hematoxylin and eosin (H&E) or anti-B220 antibody. Blood smears were stained with Wright-Giemsa (Fisher, Pittsburgh, PA).
B-cell proliferation analysis

To explore whether Tg and Tgmut constructs confer the hypothesized proliferative advantage to B cells, we measured in vitro proliferative responses to anti-CD40 and anti-IgM stimulation. Purified splenic B cells from age-matched Tg, Tgmut, and littermate control mice (20 weeks; asymptomatic by visual inspection) responded to anti-CD40 and anti-IgM (10 μg/mL). Control cells showed a maximal burst of proliferation at 24 hours and no more through 48 hours (Figure 2). Tg and Tgmut B cells proliferated at twice control levels at 24 hours and 3 times control through 48 hours. Tg and Tgmut B cells responded similarly and both underwent apoptosis in a few days. Without mitogens, Tg and Tgmut B cells did not proliferate (results not shown).

Incidence of lymphoma

All 4 founder lines of Tg and Tgmut mice sporadically developed clinical signs (ruffled fur, failure to nest, listlessness, hunched back, loss of appetite) after 28 weeks among PCR-positive littermates at approximately 10% annual incidence. Symptomatic mice were killed; spleen, thymus, liver, mesenteric lymph node, and bone marrow were examined. Splenomegaly was always apparent, accompanied by abdominal lymphadenopathy and leukemic infiltrations of liver and lung. To date, the numbers of Tg and Tgmut mice that sporadically developed lymphoma are 6 and 5, respectively, out of colonies of 38 and 59. The calculated $\chi^2$ for this dataset is 0.61, below the 3.84 value for statistical significance ($\alpha = 0.05$). Therefore, Tg is not different from Tgmut if “lymphoma” is the dependent variable. Thus, kinase function per se is not important for lymphomagenesis. Another 10% of mice die annually of causes unrelated to lymphoma or leukemia.

Tg- and Tgmut-driven B-cell lymphomas exhibit B-1 characteristics

Flow cytometry was performed with unfractionated splenocytes from leukemic Tg and Tgmut mice and compared with littermate controls. Tg and Tgmut mice did not differ significantly. The vast majority of cells were B220+ CD19+ with very few CD3+ CD4+ or CD8+ cells. Note that there are very few B220+ cells among unfractionated lymphoma cells. B220+ splenocytes expressed surface IgM, suggesting they are mature B cells, and CD5 (Figure 3A row 1). The proportion of CD5+ B220+ cells in the control is higher than usually reported because of the particular isotype control antibody used to define flow cytometry parameters. B220 was compared with CD19 to confirm B-cell lineage. Both were consistently expressed in independently arising lymphomas. The pattern of CD5 or B7-1 versus B220 is very similar to versus CD19 (Figure 3 rows 1-2). B-cell activation markers B7-1 and B7-2 were also elevated (Figure 3 row 2) and CD23 was low (Figure 3A row 3). CD11b (which associates with CD18 to form macrophage...
antigen-1 [Mac-1] and is expressed on granulocytes, natural killer [NK] cells, and macrophages) and Ly-6G (a myeloid marker) were both low (Figure 3A row 3), as was CD49b (an NK marker, results not shown), supporting the interpretation of lymphoid lineage. In addition, a number of markers for immature B cells were not detected, including CD117 (c-kit) and CD127 (interleukin-7 receptor α-chain; results not shown). Lymphoma cells were negative for CD25, syndecan-1, and CD69; positive for CD9; and showed a high IgM/low IgD ratio (Figure 3A rows 4-6). Collectively, these markers suggested that the lymphoma cells bear B-1 hallmarks.34

Levels of B7-1 and B7-2 on splenic B cells were comparable in asymptomatic Tg and Tg$^{mut}$ mice as they aged (8 through 60 weeks, not shown) and similar to those in littermate controls. Expression patterns also held constant with age for T-cell markers in asymptomatic Tg and Tg$^{mut}$ mice such as CD4 versus CD8 in spleen and thymus and CD4 versus CD25, CD4 versus CD44, CD4 versus CD62L, and CD4 versus CD69 in spleen (results not shown). However, we observed increased CD5 versus B220, CD23 versus B220, CD11b versus B220, and IgM versus IgD markers among peritoneal cells of premalignant mice with no clinical signs or splenomegaly, compared with age-matched control mice, suggesting that peritoneal B-1 cells had expanded in the premalignant mice and supporting the B-1 origin of the lymphoma.

Histochemistry of splenic lymphoma and peripheral leukemia

Lymphoid organs of asymptomatic, heterozygous Tg, and Tg$^{mut}$ mice were compared with littermate controls with B220, CD3, and H&E stains and were normal. However, spleens of leukemic mice were enlarged between × 5 and × 50, splenic architecture was disrupted (Figure 4A; Tg, panel ii; Tg$^{mut}$, panel iii), and invasive lymphoid populations showed numerous mitoses (Figure 4Av; Tg). Bone marrow showed lymphocytic lymphoma (Figure 4Avi; Tg). Elevated numbers of apoptotic cells were not observed.

Normal, syngeneic female mice were irradiated and received transplanted B cells purified from splenic lymphomas. Mice that received transplants developed leukemias and blood-clotting problems; peripheral blood contained large numbers of morphologically
similar, large lymphoblasts (Figure 4Bi). The white blood count was 790 \((\pm 40)\) \(\times 10^9/L\) \((7.9 [\pm 0.4] \times 10^5/mm^3)\). The ratio of erythrocytes to lymphoblasts was 6.6 to 1. Leukemic blasts (Figure 4Bii) exhibited scant cytoplasm, cytoplasmic vacuolation, homotypic adhesion, and abundant chromocenters that reflect mixed heterochromatin and euchromatin states, indicating transcriptional activity (Figure 4Biii). Together, these histologic features suggest greatest similarity to the centroblastic variant of diffuse large B-cell lymphoma, following current convention for classifying murine lymphoid neoplasms.38

Monoclonal immunoglobulin gene rearrangement

To determine whether the splenic B-cell neoplasm comprised a clonal or polyclonal population, total RNA from B220-selected cells was isolated for cDNA synthesis. Whereas normal littermate control spleens weighed 0.2 g and yielded approximately 300 \(\mu\)g of total RNA, spleens from lymphoma mice weighed up to 10 g and yielded 30 mg total RNA. Expressed Ig sequences were amplified with 24-mer primers to the \(3'\) constant region (\(3'\)C\(_\mu\) and \(3'\)C\(_\kappa\)) and degenerate primers to the variable regions (\(5'\)V\(_\mu\) and V\(_\kappa\)) to determine if a specific Ig gene rearrangement, or none, predominates in the expanded B-cell population.35 B220\(^+\) splenocytes of a non-Tg littermate were the control group. B-cell lymphoma RNA gave a single RT-PCR product (Figure 5A left), but polyclonal B-cell RNA gave smears with each primer pair (Figure 5A right). In this particular lymphoma, an approximately 0.5-kb product arose only from the C\(_\mu\)V\(_\mu\)1 primer pair. Cloning and sequencing identified a GenBank entry for \(Mus\ musculus\) V23-D-J-C \(\mu\) mRNA, accession no. AB069913. Three independent, monoclonal IgM\(^+\), \(\kappa\) \(^+\) B-cell lymphomas have been sequenced to date, but the number of clones remains too small to determine if the transgene promotes the emergence of a particular clonotype. Premalignant mice without clinical signs or splenomegaly showed expansion of oligoclonal splenic B cells in the weeks before clonal malignancy emerged (results not shown). We determined Bcl6 expression using real-time PCR with a standard set of primers for cDNAs synthesized from RNA of purified splenic B-cell lymphoma cells of the first and sixth passage after transplantation (to assess stability of phenotype) and compared the result with Bcl6 expression in splenic B2 cells (Figure 5B). Bcl6 expression was low and remained
compared with splenic B2 control. Relative expression levels were determined by the $Bcl6$ fi

lymphoma RNA from normal, non-Tg littermate control (right) is compared with Tg lymphoma (left). (B)
samples and to establishment of the lymphoma in the transplant recipient39,40; implanted (Figure 6). Radiation dose partly determined susceptibility RT-PCR, and resolved.

cyclin A We examined $Cyclin A$ expression

gy was 19 days (solid line). In all cases, autopsy con

died B cells puri

internal hemorrhage, and leukemic in

malignant B cells (DLCL) after irradiation with $6$ Gy was $28$ days (dotted line), whereas median survival time after irradiation with $8$ Gy was $19$ days (solid line). In all cases, autopsy confirmed that mice that received transplants died of complications from lymphoma, including massive splenomegaly, peripheral leukemia, internal hemorrhage, and leukemic infiltrates in liver and lung. Irradiated controls ($6$ Gy) that received B cells purified from an asymptomatic Tg donor survived beyond $60$ days (long dashed line). Splenocytes from Tg leukemic donors and transplants were

performed that permits proliferation in the absence of the $cyclin A$ locus, and on the cell cycle acceleration that we propose arises from $Eμ$-$BRD2$ Tg expression30 (A.S., G.V.D., unpublished data, May 2003). RT-PCR analysis of several independently arising splenic B-cell lymphomas in both Tg and Tgmut mice showed that, in all cases, $cyclin A$ transcription was elevated in the primary malignant B cells (Figure 7; lymphoma lanes 1-2) and remained stably elevated in malignant splenic B cells isolated from each passage of mice that received serial transplants that had developed B-cell lymphoma and in all individuals that received transplants, all of which developed the same lymphoma and peripheral B-cell leukemia (Figure 7; lymphoma lanes 3-4, second passage, 2 representative recipients; lymphoma 5-6, fourth passage, 2 representative recipients). $Cyclin A$ message was slightly elevated in B cells purified from asymptomatic Tg mice or Tgmut mice (Tg B cells) but barely detectable in T cells from Tg mice (Tg T cells). Tg mice with B-cell lymphoma had very few splenic T cells (Figure 3). This pattern of $cyclin A$ expression may represent a premalignant marker.

The annual rate of $10\%$ of sporadic Tg lymphoma suggests that an additional “hit” is required for tumorigenesis to progress. That second hit could be engineered various ways. We chose an amphotropic retrovirus system that expresses the $H$-ras oncogene. Tg B cells “primed” to proliferate are expected to be susceptible to cooperation with the activated ras gene. Lymphomagenesis was accelerated from several months to $4$ weeks. Seven Tg and 7

of the $cyclin A$ locus, and on the cell cycle acceleration that we propose arises from $Eμ$-$BRD2$ Tg expression (A.S., G.V.D., unpublished data, May 2003). RT-PCR analysis of several independently arising splenic B-cell lymphomas in both Tg and Tgmut mice showed that, in all cases, $cyclin A$ transcription was elevated in the primary malignant B cells (Figure 7; lymphoma lanes 1-2) and remained stably elevated in malignant splenic B cells isolated from each passage of mice that received serial transplants that had developed B-cell lymphoma and in all individuals that received transplants, all of which developed the same lymphoma and peripheral B-cell leukemia (Figure 7; lymphoma lanes 3-4, second passage, 2 representative recipients; lymphoma 5-6, fourth passage, 2 representative recipients). $Cyclin A$ message was slightly elevated in B cells purified from asymptomatic Tg mice or Tgmut mice (Tg B cells) but barely detectable in T cells from Tg mice (Tg T cells). Tg mice with B-cell lymphoma had very few splenic T cells (Figure 3). This pattern of $cyclin A$ expression may represent a premalignant marker.

unaltered over 6 months of serial transplantations, described in the next paragraph.

Transplantation

Malignant B cells were purified from Tg lymphoma and transplanted (Figure 6). Radiation dose partly determined susceptibility to establishment of the lymphoma in the transplant recipient39,40, median survival time for mice that received transplants of $10^7$ malignant B cells (DLCL) after irradiation with $6$ Gy was $28$ days (dotted line), whereas median survival time after irradiation with $8$ Gy was $19$ days (solid line). In all cases, autopsy confirmed that mice that received transplants died of complications from lymphoma, including massive splenomegaly, peripheral leukemia, internal hemorrhage, and leukemic infiltrates in liver and lung. Irradiated controls ($6$ Gy) that received B cells purified from an asymptomatic Tg donor survived beyond $60$ days (long dashed line). Splenocytes from Tg leukemic donors and transplants were

indistinguishable by flow cytometry, Ig gene rearrangement, in vivo growth characteristics, organ sites of leukemic infiltration, or morphology of peripheral blood lymphoblasts (results not shown), suggesting the characteristics of the B-cell lymphoma were stable, even after $6$ serial transplantations. The lymphoma cannot be maintained in ordinary tissue culture, as the cells appear not to have undergone an immortalizing event that permits proliferation in media without B-cell mitogens (lipopolysaccharide, interleukin-4, or anti-CD40 + anti-IgM). We have maintained individual lymphoma clones by serial transplantation into irradiated recipients.

**Cyclin A expression**

We examined $cyclin A$ transcription in the malignant cells, based on our published model for Brd2-dependent transcriptional activation

Figure 5. Immunoglobulin gene rearrangements are monoclonal. (A) Ig RNAs were isolated from purified B cells of a Tg splenic B-cell lymphoma, amplified by RT-PCR, and resolved. – RT control is shown (left). Primers to the 3′ constant region (3′Cγ and 3′Cκ) Ig sequences and degenerate primers to the variable regions (5′VH and 5′VK) were used in pairs as indicated. RNA of purified, polyclonal B cells from normal, non-Tg littermate control (right) is compared with Tg lymphoma (left). (B) Lymphoma RNA from first or sixth transplanted passage of malignancy was amplified with primers specific for Bc6 or Blimp-1 genes by real-time PCR and compared with splenic B2 control. Relative expression levels were determined by the 2–ΔΔCt method where $ΔΔCt = ΔCt_{sample} – ΔCt_{reference}$ with Bc6 or Blimp-1 serving as samples and $\beta2$-microglobulin as a reference.
non-Tg mice were injected intraperitoneally with either H-ras–expressing amphotrophic retrovirus or neo-expressing retrovirus alone. After 4 weeks, Tg mice injected with the H-ras retrovirus developed severe splenomegaly; non-Tg mice injected with H-ras did not develop illness. Analysis of histopathology, flow cytometry of cell surface antigens, transplantability, and monoclonality of Ig gene rearrangements indicated a diagnosis of B-cell lymphoma indistinguishable from sporadic cases. We then performed Affymetrix GeneChip analysis with B-cell RNA purified from both sporadic and ras-accelerated splenic lymphomas. Controls were, respectively, normal B cells purified from normal littermate controls and from apparently normal mice injected with neo retrovirus. The 3 mouse arrays A, B, and C permitted whole-genome analysis of the transcriptome of the Brd2-induced lymphomas, resulting in molecular signatures for malignancy that we compared with published databases of human lymphomas. Selected significant markers for named genes are shown in Table 1.

In the Tg B-cell lymphoma, most transcriptional changes of greatest estimated significance were 50- to 100-fold decreases in mouse immune cell markers, mostly Ig gene κ-chain sequences (results not shown). Because the B-cell lymphomas are monoclonal, the transcriptomes show a marked decrease in the abundance of diverse Ig gene transcripts when compared with the polyclonal Ig gene transcripts found in the normal littermate B-cell controls. In analyses of the most significant fold changes, we excluded Ig gene sequences because of this trivial explanation. To a first approximation, the transcriptome indicates similarity to diffuse large B-cell lymphoma (DLCL) in humans, the most common type of non-Hodgkin lymphoma.41 Histopathology supports this conclusion. The molecular signature of other B-cell phenotypes, such as resting or activated B cells in the peripheral blood, B-cell follicular lymphoma, transformed B-cell lines, or B-cell chronic lymphocytic leukemia, are not characteristic of this B-cell lymphoma.41 The sporadically arising Tg B-cell lymphomas (Table 1; sporadically arising Tg B-cell lymphomas [SPORs]) and ras-accelerated lymphomas (RASs) shared a close but not identical molecular signature. Most fold changes of named marker genes identified in the literature as lymphoid biomarkers were changed in the same direction and often by a similar magnitude in sporadic and ras-accelerated Tg lymphomas. The Tg lymphoma transcriptional signature did not resemble signatures of human DLCL cases independently established through clinical measures to have a favorable or unfavorable prognosis42 (results not shown). We did not observe a good correlation between the Tg lymphoma transcriptional signature and signatures41,42 of either germinal center–like or activated B-cell–like human DLCLs (Table 1).

Discussion

We designed transgenic mice to test our hypothesis that constitutive expression of BRD2 in the lymphoid compartment would cause lymphoproliferative disease. We based this hypothesis on substantial in vitro evidence that ectopic overexpression of Brd2 transactivates E2F-regulated cell cycle genes such as cyclin D1, cyclin E, cyclin A, and dihydrofolate reductase in synergy with oncogenic ras38 and that Brd2 participates in transcription complexes that contain a histone H4–specific HAT activity and E2F proteins. Furthermore, Brd2 responds to mitogenic signals; when overexpressed, it transforms NIH/3T3 fibroblasts in synergy with ras and accelerates the G1 → S transition through direct action on the cyclin A promoter. Double bromodomain proteins such as Brd2 have been insufficiently studied. The occurrence of a B-cell lymphoma in these transgenic mice now establishes a link between this class of proteins and neoplasia.

Table 1. Molecular signature of Tg B-cell lymphoma

<table>
<thead>
<tr>
<th>Gene</th>
<th>SPOR</th>
<th>RAS</th>
<th>GC</th>
<th>AB</th>
<th>FL</th>
<th>AT</th>
<th>TC</th>
<th>RPB</th>
<th>CLL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bcl2</td>
<td>+1.6</td>
<td>+2.7</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Bcl6</td>
<td>-4.4</td>
<td>-13.4</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Casp1</td>
<td>+5.0</td>
<td>+3.2</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ccn1</td>
<td>+2.9</td>
<td>+1.6</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Ccnb1</td>
<td>+2.4</td>
<td>+2.4</td>
<td>0</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ccone2</td>
<td>+3.1</td>
<td>+8.7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cd3d3</td>
<td>-30.1</td>
<td>-2.6</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Cd3d3</td>
<td>-40.8</td>
<td>-2.6</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Cd3d8</td>
<td>+1.6</td>
<td>+3.2</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cd44</td>
<td>+10.6</td>
<td>+5.9</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cdk5</td>
<td>+1.6</td>
<td>+2.6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Cdk1</td>
<td>-3.1</td>
<td>-1.4</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fos</td>
<td>+5.22</td>
<td>+2.0</td>
<td>0</td>
<td>0</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pkcb</td>
<td>+2.4</td>
<td>+2.0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Rara</td>
<td>-6.5</td>
<td>-18.0</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rb1</td>
<td>+2.2</td>
<td>+2.1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Spib</td>
<td>+1.5</td>
<td>+2.8</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tcrb</td>
<td>-5.7</td>
<td>-3.9</td>
<td>0</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tubb1</td>
<td>-6.1</td>
<td>-1.9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Vegfa</td>
<td>-9.5</td>
<td>-6.6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Most significant changes in expression profile of named genes in lymphoma compared with control. About one third of the genome (12000 genes) was significantly expressed. Given the preliminary estimate of variance, about 35% of these were differentially expressed. Comparisons are made to entries in the online databases of Alizadeh et al43 and Shipp et al.44 DLCL indicates diffuse large B-cell lymphoma; SPOR, sporadic Tg B-cell lymphoma; RAS, ras-accelerated Tg B-cell lymphoma; GC, germinal center-like lymphoma41,42; AB, activated peripheral B-cell-like lymphoma41,42; FL, B-cell follicular lymphoma (morphology as a whole); AT, activated/resting T cell41; TC, transformed cell line41; RPB, resting peripheral B cell41; CLL, B-cell chronic lymphocytic leukemia41; +, small increase; ++, large increase; +++, very large increase; and −, no change; and o, no report, no significant change, or no consistent change within a subclass.

Gene entries (mouse gene abbreviation/human homolog, name): Bcl2/BCL2 indicates B-cell leukemia/lymphoma 2; Bcl6/BCL6, B-cell leukemia/lymphoma 6; Casp1/CASP1, caspase-1; Ccn1/CCNA1, cyclin A1; Ccnb1/CCNB1, cyclin B1; Ccn2/CCNE1, cyclin E2; Cd3d/CD3D, CD3 antigen, β polypeptide; Cd3e/CD3E, CD3 δ antigen, γ polypeptide; Cd48/CD38, CD38 antigen; Cd44/CD44, CD44 antigen; Cdk5/CDK5, cyclin-dependent kinase 5; Ches1/CHES1, checkpoint suppressor 1; Fos/FOS, FBXW7/PSIT, Brd2/FAC1, bromodomain-containing protein 1; Rara/RARa, retinoic acid receptor α; Rb1/RB1, retinoblastoma protein; Spib/SPIB, Sp1 transcription factor (Sp1-1PU1 related); Tcrb/TCRB, T-cell receptor γ chain; Tubb1/TUBB1, tubulin β1; Vegfa/VEGF, vascular endothelial growth factor A.

Most significant fold-changes are compared with Shipp et al.44 Figure 5 (DLCL with GC-like vs AB-like signature) and Alizadeh et al.43 Table 1 (transcriptional profiles of various lymphoid cell types, including GC and AB signatures)
partners likely encode oncoproteins. Also, translocations that fuse the bromodomain and HAT domain of CBP to the mixed-lineage leukemia factor (MLL; also called All-I) or to the monocytic leukemia zinc finger protein, or that fuse P300 to MLL, create oncoproteins that are associated with acute leukemias (reviewed in Filetici and Ballario). The bromodomain is required for full transforming activity in at least one of these cases. Deletion of the Brd2 bromodomain destroys Brd2-dependent transcriptional activation of cyclin A (G.V.D., unpublished data, May 2003) and eliminates association of Brd2 with the multiprotein complex that contains a histone H4–specific HAT and E2F proteins.

Ectopic expression of Brd2 leads both to cell cycle destabilization and transformation in synergy with oncogenic ras or its effectors. We hypothesized that E4-directed expression of BRD2 in the lymphoid compartment would lead to leukemogenesis or lymphoma, and we obtained this result. Malignant cells from enlarged spleens bear cell surface markers consistent with B-1 lineage. This apparently differentiated phenotype remains constant after 6 serial transplantations, with respect to antigen expression in flow cytometry, Ig gene rearrangement, in vivo growth characteristics, elevated cyclin A transcription, organ sites of leukemic infiltration, and morphology. From these data we speculate that the malignant cells do not have a high degree of genetic instability or flexibility in their transcriptional profile. Transcriprome analysis over time will be necessary to confirm this supposition.

The Drosophila homolog of BRD2 is female sterile homeotic, which encodes a homeotic protein and probable transcriptional activator that is upstream activator of the trithorax locus. The human homolog of trithorax, is disrupted in mixed-lineage (myeloid and lymphoid) human leukemias associated with 11q23 translocations. The functional relationships established in Drosophila (between fsh and trithorax) may be conserved in humans (between Brd2 and MLL), as we hypothesized.

We therefore looked for a mixed-lineage leukemic phenotype in the mice that received leukemic transplants, but flow cytometry suggests that myeloid components are not present among the leukemic B cells.

We have proposed a mechanism for Brd2-driven transcriptional activation of important cell cycle regulatory genes. Brd2 recruits both E2F proteins and HAT activity to the cyclin A gene in particular (A.S., G.V.D., unpublished data, May 2003). These results agree with literature that has established a dual role for E2F proteins.

Ectopic overexpression of Brd2 transactivates a heterologous cyclin A promoter luciferase construct in synergy with mitogenic signals from ras or MEKK, an effector of ras, and increases expression of endogenous cyclin A in synchronized fibroblasts that have been stimulated to enter the cell cycle; these cells show Brd2-driven accelerated kinetics of S-phase entry and mobilization of cyclin A–associated cdk activity (A.S., G.V.D., unpublished data, May 2003). Accordingly, we examined cyclin A transcription in B220+ cells purified from several sporadically arising Tg B-cell lymphomas, compared with B220+ cells from asymptomatic Tg controls. Cyclin A is under negative transcriptional control until S phase, and is frequently elevated in tumors; it is indeed transcriptionally activated in the Tg malignancy and slightly activated in B cells from asymptomatic Tg mice but not T cells. Therefore, the transgene destabilizes cyclin A in B cells as predicted.

The morphology, surface antigen phenotype, and transcriptionome signature of Eqo-BRD2–driven B-cell lymphomas suggest they are most related to human non-Hodgkin lymphomas of the DLCL type. BRD2 is not present in lymphoma databases we queried, so comparison of its level in lymphoid malignancies was not possible. We queried Cancer Genome Anatomy Project databases for evidence of transcriptional up-regulation of Brd2 message in human malignancies and found an increase of 4.2 fold (P = .04) reported for 3 cancerous or precancerous lymph nodes compared with 4 normal lymph node controls. Furthermore, the Mittelman database (http://cgap.nci.nih.gov/chromosomes/mitelman) of recurrent chromosomal abnormalities associated with cancer identifies 386 references and 546 patient hematologic malignancies involving breakpoints at 6p21, which includes the class II histocompatibility complex wherein BRD2 is located, but only a small minority have received fine-structure mapping. Therefore, whereas some cases are likely to show breakpoints within the BRD2 locus, insufficient data exist to make generalizations about the role of BRD2 in the pathogenesis of human DLCL.

Human DLCLs exhibit a variety of genetic abnormalities. The most common is structural alteration of the BCL6 locus, often resulting in deregulated BcI6 activity. We determined that BcI6 transcript levels are low in Tg B-cell lymphoma, consistent with the view that BcI6 activation is more commonly associated with lymphoblastic lymphoma in mice; furthermore the BcI6 locus is not normally mutated in mouse B-cell lineage lymphomas. Unaltered BcI6 transcript levels in Tg lymphoma are also consistent with the posited function of the Tg as a transcriptional coactivator and cell cycle regulator; no current evidence shows a role for BRD2 overexpression in genetic instability.

Human DLCL is thought to arise from germinal center B cells, or less commonly, from marginal zone B cells. However, our expression profile data indicate that the Tg B-cell malignancy does not obviously share a signature with any subclass of human DLCL, and flow cytometry analysis unambiguously identifies the Tg malignancy as composed of B-1 cells. A subclass of murine DLCL, which has neither follicular nor marginal zone origins, has been discussed and seems appropriate to classify this Tg lymphoma. An ongoing theme in the lymphoma literature is the extreme
diversity of DLCL. Expression profile data demonstrate that even among ostensibly “biomarker” genes for specific subclasses of DLCL or clinical outcomes, relevant variance exists across cases, as though each DLCL ought to be considered a completely unique neoplasm. Nevertheless, expression profiling with DNA microarrays remains the best method so far to link specific DLCLs with prognosis and most effective course of treatment. In addition, whereas splenic lymphoma cells inoculated subcutaneously into irradiated transplant recipients (Figure 6) exhibit a stable splenic B-1 phenotype after several months of serial transplantations, intraperitoneal inoculation shifts the phenotype to peritoneal B-1 after only a few days (J.R.T., T.L.R., G.V.D., unpublished observations, June 2003), suggesting that environment partially determines the transcriptome. Previously profiled B lymphocytes were obtained from tonsils, peripheral blood, cord blood or lymph nodes, or lymph nodes alone, from spleen as in our case, so both organ sites and species variation likely contributed to differences between databases and our profiles. Interestingly, cyclin A is elevated in several subclasses of DLCL but not in all cases; DLCL pathogenesis could conceivably follow multiple routes from initiation to malignancy. The early elevation of cyclin A transcription in Tg B cells (Figure 7) may represent a premalignant change. Inroads are just being made into understanding the transcriptional and coactivator functions of double bromodomain proteins such as Brd2. The Tg-dependent transcriptional up-regulation of cyclin A represents a novel pathway for B-cell proliferation and may represent a useful model for lymphomagenesis.

Like the Eμ-BRD2 system, the well-known Eμ-myc system causes B-lineage–restricted malignancies that are monoclonal for Ig gene rearrangement, resemble non-Hodgkin lymphomas, and may exhibit a lengthy premalignant phase. This latent period, beginning prematurely, during which the myc transgene is active throughout the entire B-lymphoid compartment, suggests that an additional genetic change is required to effect full malignant transformation. However, unlike Eμ-myc mice, the B-cell lymphomas of Eμ-BRD2 mice comprise only mature B cells, despite Eμ activity early in B-cell development and despite the TAF-like properties of Brd2. We propose that Eμ-BRD2 acts at a specific, late stage of B-cell development, probably on the B-1 compartment, to promote the proliferation that gives rise to the DLCL presentation; we will investigate this system further. Weinberg and colleagues originated a model of oncogenesis wherein cooperation between different oncogenes such as myc and ras greatly increases the frequency of neoplastic transformation; we observe analogous behavior here with acceleration of Eμ-BRD2–driven lymphomagenesis. It would be interesting to determine whether myc synergizes with Brd2 by mating Eμ-myc mice with Eμ-BRD2 mice. Deregulated recruitment of HATs to susceptible promoters may provide a common mechanism for myc- and Brd2-dependent tumorigenesis, as myc has been shown to recruit transcription transformation domain-associated protein (TRRAP)– and Gcn5-associated HAT activities, and TRRAP and Gcn5 also interact with E2F-1 and E2F-4 transactivation domains, suggesting a model of transcriptional activation dependent on both specific promoter-bound transcriptional activators and recruited HATs to account for the oncogenic activity and E2Fs, recapitulating the link between HATs and E2Fs that Brd2 provides.

Given the pleiotropic nature of similar bromodomain “scaffold,” coactivators, and TAFs, such as TAFII250, improper activation of cyclin A is unlikely to be the sole consequence of deregulated Brd2 signaling. Other transcriptional targets are likely to exist; Brd2 may not act solely in S phase. We speculate that some of these targets include virally transactivated genes associated with neoplasia, because Brd2 interacts with the latent nuclear antigen of Kaposi sarcoma–associated herpesvirus (HSV-8), which also targets E2F-regulated genes. We expect future studies will illuminate the role of bromodomain proteins as a scaffold that recruits chromatin restructing activities and transcription factors to the cyclin A promoter, not unlike studies in TAFII105 dominant-negative transgenic mice, which have revealed interactions between transcription activators and TAFs that have consequences for nuclear factor κB (NFκB) signaling and survival in B and T cells. Understanding how Brd2 functions in normal cells should provide insight into the origins and nature of B-cell lymphomas that are promoted by improper Brd2 signaling in B cells.

Acknowledgments

We thank Stephan Beck for cDNA that encodes Brd2; Philip Leder for pIgTE/N vector; Katya Ravid and the Transgenic Core Facility of Boston University School of Medicine (BUSM) for production of transgenic founders; Robin MacDonald of the BUSM Laboratory Animal Science Center for help with the mouse colony; Sherrie Sharp for help with flow cytometry; Bill Joyce for help with hematology; Robert J. Munn and Judith Wallis for help with histology; Joan Press for help with determining immunoglobulin gene clonality; Norman Gerry, Marc Lenburg, and Garrett Frampston of the BUSM Microarray Resource for help with Affymetrix GeneChip technology; and Mary Ballestas, Janet Buhlmann, David Seldin, and Nancy Zeleznik-Le for critical review of the manuscript.

References

1. Denis GV. Bromodomain motifs and “scaffold- ing”? Front Biosci. 2001;6:D1066-D1068.
37. Kemp DJ, Harris AW, Adams JM. Transcripts of
36. Kemp DJ, Harris AW, Cory S, Adams JM. Expres-
34. Hardy RR, Hayakawa K. B cell development
33. Seldin DC, Leder P. Casein kinase II alpha trans-
32. Schmidt EV, Pattengale PK, Weir L, Leder P.
28. Guo N, Faller DV, Denis GV. Activation-induced
15. Rachie NA, Seger R, Valentine MA, Ostrowski J,
26. Rachie NA, Seger R, Valentine MA, Ostrowski J,
25. Denis GV, Green MR. A novel, mitogen-activated
23. Filetici P, Ballario P. The bromodomain: a chro-
75. Radkov SA, Kellam P, Boshoff C. The latent
74. Platt GM, Simpson GR, Mittnacht S, Schulz TF.
72. McMahon SB, Van Buskirk HA, Dugan KA, Cope-
63. Pasqualucci L, Migliazza A, Basso K, Hould-
62. Ye BH, Chaganti S, Chang CC, et al. Chromo-
60. Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle
59. Lange-Carter CA, Johnson GL. Ras-dependent
58. Knudsen KE, Fribourg AF, Strobeck MW, Blan-
57. Clarke AS, Lowell JE, Jacobson SJ, Pillus L.
56. Poon RY, Poon RF, Poon RY. Cyclin A in cell cycle
55. Gaeta-encoding gene, BCL-6, in diffuse
54. Frank SR, Schroeder M, Fernandez P, Taubert S,
53. Radkov SA, Kellam P, Buskirk HA, Dugan KA,
52. Gans M, Forquignon F, Masson M. The role of
51. Langdon WY, Harris AW, Cory S, Adams JM. The c-
50. Langdon WY, Harris AW, Cory S, Adams JM. The c-
49. Borrow J, Stanton Jr VP, Andresen J, et al. The trans-
48. Sobulo OM, Borrow J, Tomek R, et al. MLL is
44. Gu Y, Nakamura T, Alder H, et al. The f(4;11)
43. Filetici P, Ballario P. The bromodomain: a chro-
42. Dey A, Ellenberg J, Farina A, et al. A bromodo-
40. French CA, Miyoshi I, Kubonishi I, Grier HE,
38. Morse HC, Anver MR, Fredrickson TN, et al. He-
37. Kemp DJ, Harris AW, Adams JM. Transcripts of
36. Kemp DJ, Harris AW, Cory S, Adams JM. Expres-
35. Denis GV, Green MR. A novel, mitogen-activated
34. Seldin DC, Leder P. Casein kinase II alpha trans-
33. Filetici P, Ballario P. The bromodomain: a chro-
32. Schmidt EV, Pattengale PK, Weir L, Leder P.
30. Du J, Nasir I, Benton BK, Kladde MP, Laurent BC.
29. Sobulo OM, Borrow J, Tomek R, et al. MLL is
28. Guo N, Faller DV, Denis GV. Activation-induced
26. Rachie NA, Seger R, Valentine MA, Ostrowski J,
25. Denis GV, Green MR. A novel, mitogen-activated
23. Filetici P, Ballario P. The bromodomain: a chro-
0. Dey A, Ellenberg J, Farina A, et al. A bromodo-
Eµ-\textit{BRD2} transgenic mice develop B-cell lymphoma and leukemia

Rebecca J. Greenwald, Joseph R. Tumang, Anupama Sinha, Nicolas Currier, Robert D. Cardiff, Thomas L. Rothstein, Douglas V. Faller and Gerald V. Denis